KDI 792

Also Known As:

(5Z)-6-((2S,4R)-4-(4-chlorophenylsulphonylamino)-1-(3-pyridylmethyl)-2-pyrrolidinyl) 5-hexenoic acid; FK070; KDI-792

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Diabetic Neuropathies (Diabetic Neuropathy) 08/01/1995 - "Improvement in blood flow and diabetic neuropathy by thromboxane A2 dual blocker KDI-792."
2.	Diabetic Retinopathy (Retinopathy, Diabetic) 01/01/1996 - "To clarify the involvement of the prostaglandin (PG)-thromboxane (TX) system in diabetic retinopathy, the production of thromboxane A2 (TXA2), prostaglandin I2 (PGI2) and prostaglandin E2 (PGE2) and the effects of a thromboxane synthase inhibitor (TXSI; KDI-792; 5Z-6[(2S,4R)-4-(4-chlorophenylsulfonylamino)-1-(3-pyridyl methyl)-2 pyrrolidinyl]-5-hexenoic acid hydrochloride) were examined under high glucose concentration using bovine retinal endothelial cells. "